本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Oyster Point Pharma

11.17
0.0000
成交量:- -
成交額:2,331.11萬
市值:3.03億
市盈率:-1.68
高:11.17
開:11.17
低:11.17
收:11.17
52周最高:18.30
52周最低:3.46
股本:2,714.48萬
流通股本:893.31萬
量比:- -
換手率:- -
股息:- -
股息率:- -
每股收益(TTM):-6.6407
每股收益(LYR):-3.8661
淨資產收益率:-306.38%
總資產收益率:-65.11%
市淨率:-13.66
市盈率(LYR):-2.89

資料載入中...

2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/01/13

重要事件披露

8-K/A [Amend] - Current report
2023/01/13

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/09

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/05

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/03

交易所摘牌聲明

25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2023/01/03

重要事件披露

8-K - Current report
2023/01/03

員工持股計劃

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/01/03

員工持股計劃

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/01/03

員工持股計劃

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/01/03

員工持股計劃

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2022/12/21

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/11/21

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/11/10

重要事件披露

8-K - Current report
2022/11/10

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/11/08

重要事件披露

8-K - Current report
2022/11/07

重要事件披露

8-K - Current report
2022/08/11

重要事件披露

8-K - Current report